All In Biotech

Drug Trial Radar · NCT05020015

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

27

Actual

Start

Nov 12, 2021

Primary completion

Jun 16, 2024

Study completion Dec 20, 2038

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease responds to treatment with TAK-007 in adults with r/r B-cell NHL or iNHL. Participants will receive 3 days of chemotherapy to reduce a type of white blood cells called lymphocytes, in the blood. This is called lymphodepleting chemotherapy (LDC) or lymphodepletion. After LDC, patients will receive a single injection of TAK-007 or three weekly injections of TAK-007 (multi-dose injection). After this, participants will regularly visit the clinic for check-ups.

Conditions

  • Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Interventions

  • TAK-007Biological

    TAK-007 intravenous injection.

  • Chemotherapy AgentsDrug

    Fludarabine and cyclophosphamide as per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 24 months
  2. Number of Participants With Clinically Significant Changes in Laboratory ParametersTime frame: Up to 24 months
  3. Number of Participants With Notable Changes in Vital SignsTime frame: Up to 24 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California

  • MedStar Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Sylvester Comprehensive Cancer Center University of Miami Hospitals and Clinics

    Miami, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Columbia University Medical Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • DUHS Duke Blood Cancer Center

    Durham, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Thomas Jefferson University Sidney Kimmer Cancer Center, Clinical Research Organization

    Philadelphia, Pennsylvania

  • Saint Davids South Austin Medical Center

    Austin, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.